United Therapeutics (Nasdaq: UTHR) is a very smart, very innovative, and very profitable company.

First it treated an untreatable disease. Now it's disrupting the entire organ transplant industry.

In today's show, 7investing CEO Simon Erickson introduces United Therapeutics, describing why the company was created and its five commercially-approved drugs.

He also explains how its four synthetic organ programs could disrupt the entire organ transplant market.

See why United Therapeutics is a stock that should be on your radar. To join our free email list, visit 7investing.com/email.